DAFNA Capital Management LLC Has $1.26 Million Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

DAFNA Capital Management LLC lifted its stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 85.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,511,374 shares of the company’s stock after acquiring an additional 1,160,666 shares during the period. DAFNA Capital Management LLC’s holdings in Lineage Cell Therapeutics were worth $1,262,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Defender Capital LLC. grew its holdings in shares of Lineage Cell Therapeutics by 19.2% during the fourth quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock worth $2,997,000 after purchasing an additional 961,150 shares during the last quarter. Raffles Associates LP increased its stake in Lineage Cell Therapeutics by 21.8% in the fourth quarter. Raffles Associates LP now owns 5,492,088 shares of the company’s stock valued at $2,760,000 after purchasing an additional 984,307 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Lineage Cell Therapeutics in the 4th quarter valued at $1,984,000. Renaissance Technologies LLC increased its position in shares of Lineage Cell Therapeutics by 1,058.3% in the 4th quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company’s stock valued at $1,147,000 after buying an additional 2,085,972 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Lineage Cell Therapeutics by 39.8% during the 4th quarter. JPMorgan Chase & Co. now owns 946,399 shares of the company’s stock worth $476,000 after buying an additional 269,237 shares during the period. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. D. Boral Capital restated a “buy” rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. B. Riley cut their price objective on Lineage Cell Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, March 14th. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. Finally, Maxim Group reduced their price objective on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Friday, January 10th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Lineage Cell Therapeutics currently has an average rating of “Buy” and an average price target of $4.20.

Lineage Cell Therapeutics Stock Up 2.1 %

NYSEAMERICAN LCTX opened at $0.44 on Thursday. The firm has a market cap of $97.87 million, a P/E ratio of -3.70 and a beta of 1.21. The company’s 50 day moving average is $0.47 and its 200-day moving average is $0.64. Lineage Cell Therapeutics, Inc. has a 12-month low of $0.37 and a 12-month high of $1.26.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.